Recorded fact · drug.label_indication
drug.label_indication for apalutamide|prostate-cancer
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact d1afd5b5 resolves to.
The record
| Fact id | d1afd5b553d20a60d8d33853 |
|---|---|
| Entity | drug: apalutamide|prostate-cancer |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260702 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 2bf101e0b05b6e0c73cad16f5aa59514724cb5cefc24c30ba02462b4c9e1458c.
The value
{
"ingredient": "APALUTAMIDE",
"conditionId": "prostate-cancer",
"conditionName": "Prostate Cancer",
"matchedAlias": "prostate cancer",
"context": "indication",
"brand": "ERLEADA",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "d1cda4f7-cb33-46ea-b9ac-431f6452b1a5",
"labelEffectiveTime": "20260702",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 709af836bac483060739c7d64c97e03f982fc677dc42034bde332363587d59ea.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.